Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Ushers In Era of New Drug Manufacturing Technologies

Executive Summary

FDA's Emerging Technology Team is guiding a diverse array of new manufacturing technologies through the agency's regulatory review process that could add market niches and possibly even fundamentally restructure the pharmaceutical industry.

Advertisement

Related Content

Disease-Specific Drug Development Guidances Coming From US FDA In 2018
FDA Approves First Digital Pill: Otsuka/Proteus' Abilify MyCite
FDA Approves First Digital Pill: Otsuka/Proteus' Abilify MyCite
US FDA Progress Report Highlights Biomarkers, Continuous Manufacturing, Antibiotic Testing
Focus On Equipment And Software For Validating Continuous Manufacturing Processes – FDA

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS057716

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel